 |
 |
 |
||||||||||||||
|
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
||||
| < 2005 News Listings | ||||||||||||||||
|
CAMBRIDGE, MA April 19, 2005 Archemix Corp., the privately-held biopharmaceutical company focused on discovering and developing aptamer-based therapeutics, announced today the appointment of Michael Kallelis as Vice President of Manufacturing. Mr. Kallelis will have responsibility for directing the Company's Manufacturing Group and all related efforts. Prior to joining Archemix, Mr. Kallelis served as the Executive Vice President and General Manager of Avecia Biotechnology, Inc. Over a 24-year manufacturing career, Mr. Kallelis has developed significant experience and expertise in solid phase oligonucleotide synthesis and process development of phosphoramidites. In his role at Avecia, Mr. Kallelis managed one of the single largest oligonucleotide synthesis plants in the world. Prior to joining Avecia, Mr. Kallelis co-founded and served as Chief Operating Officer of Boston BioSystems, Inc., a major producer of oligonucleotides for therapeutics and diagnostics. In this role, Mr. Kallelis managed all chemical operations, oligonucleotide production and process development. Mr. Kallelis has also held various operating positions at BioSepra and Millipore Corporation. Mike has extensive experience in the area of oligonucleotide synthesis and process development and will lead this important multifunctional area at Archemix, said Dr. Errol De Souza, President and Chief Executive Officer of Archemix. "Mike possesses the unique combination of manufacturing experience and operational leadership skills necessary to ensure that our manufacturing capabilities keep pace with our rapidly expanding pipeline of therapeutic aptamers. We are delighted to have Mike as a part of our team and look forward to his contributions and the generation of shareholder value." "Archemix is at an exciting stage of its development," commented Mr. Kallelis. "I look forward to leveraging my experience in oligonucleotide synthesis and process development to bolster Archemix's chemistry, manufacturing and controls (CMC) efforts. Our efforts in manufacturing and process development will support an exiting and burgeoning pipeline of aptamer therapeutics." About Aptamers Aptamers are single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind to target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical and biological stability, low toxicity and immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed, offering a significant cost advantage. As therapeutic agents, aptamers have demonstrated clinical biological efficacy and have excellent, tunable pharmacokinetic properties. About Archemix Corp. Archemix Corp. is a privately-held biopharmaceutical company based in Cambridge, Massachusetts. The company's mission is to develop aptamers as a class of directed therapeutics for the treatment of human disease. Because of their unique properties and proven efficacy, aptamers are a superior alternative to biologics and small molecules and will be a major class of drugs for the treatment of unmet medical needs. Archemix's aptamer expertise is complimented by a dominant patent estate comprised of over 220 issued and 230 pending patents covering the identification, composition and use of therapeutic aptamers. In addition to the company's core aptamer generation technology, Archemix possesses strong expertise in both preclinical and clinical drug development. Further information about Archemix can be found at http://www.archemix.com. For further information, or to speak with Michael Kallelis or Dr. Errol De Souza, please contact Davia Temin or Jane Trombley of Temin and Company at 212-588-8788 or news@teminandco.com. |
|
|
Copyright ©2007 Rho Capital Partners, Inc.